(Q42249892)

19 October 2017

title

High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis (English)

1 reference

19 October 2017

1 reference

2

Jessica Cusato

1 reference

19 October 2017

Andrea Calcagno

1

1 reference

19 October 2017

Marco Simiele

3

1 reference

19 October 2017

Ilaria Motta

4

1 reference

19 October 2017

Sabrina Audagnotto

5

1 reference

19 October 2017

Margherita Bracchi

6

1 reference

19 October 2017

Antonio D'Avolio

7

1 reference

19 October 2017

Giovanni Di Perri

8

1 reference

19 October 2017

Stefano Bonora

9

1 reference

19 October 2017

language of work or name

English

0 references

publication date

23 August 2013

1 reference

Journal of Antimicrobial Chemotherapy

19 October 2017

published in

1 reference

19 October 2017

volume

69

1 reference

19 October 2017

issue

1

1 reference

19 October 2017

page(s)

241-245

1 reference

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT339

Raltegravir cerebrospinal fluid concentrations in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT339

Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT339

Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT339

Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT339

Organic anion transport in choroid plexus from wild-type and organic anion transporter 3 (Slc22a8)-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT339

The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT339

Expression of HNF4alpha in the human and rat choroid plexus: implications for drug transport across the blood-cerebrospinal-fluid (CSF) barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT339

Hepatocyte nuclear factor-4{alpha} regulates the human organic anion transporter 1 gene in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT339

Organic anion transport pathways in antiviral handling in choroid plexus in Oat1 (Slc22a6) and Oat3 (Slc22a8) deficient tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT339

An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT339

HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT339

Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT339

Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT339

Etravirine in CSF is highly protein bound

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT339

Blood-brain barrier damage and brain penetration of antiepileptic drugs: role of serum proteins and brain edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT339

Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT339

Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT339

21 January 2018

Identifiers

DOI

10.1093/JAC/DKT339

1 reference

19 October 2017

1 reference